PE20211078A1 - Proteinas de fusion de peptido similar al glucagon 1 (glp1)-factor de diferenciacion de crecimiento 15 (gdf15) y usos de estas - Google Patents

Proteinas de fusion de peptido similar al glucagon 1 (glp1)-factor de diferenciacion de crecimiento 15 (gdf15) y usos de estas

Info

Publication number
PE20211078A1
PE20211078A1 PE2021000543A PE2021000543A PE20211078A1 PE 20211078 A1 PE20211078 A1 PE 20211078A1 PE 2021000543 A PE2021000543 A PE 2021000543A PE 2021000543 A PE2021000543 A PE 2021000543A PE 20211078 A1 PE20211078 A1 PE 20211078A1
Authority
PE
Peru
Prior art keywords
glp1
gdf15
fusion proteins
glucagon
differentiation factor
Prior art date
Application number
PE2021000543A
Other languages
English (en)
Inventor
Matthew M Rankin
Xiefan Lin-Schmidt
Chichi Huang
Jennifer Furman
Songmao Zheng
Shamina Rangwala
Serena M Nelson
Shannon Mullican
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PE20211078A1 publication Critical patent/PE20211078A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente descripcion se proporcionan proteinas de fusion de GLP1-GDF15 que comprenden un GLP1 o un peptido variante de GLP1, un primer peptido enlazador, una proteina de albumina serica, un segundo peptido enlazador, y una proteina GDF15
PE2021000543A 2018-10-22 2019-10-22 Proteinas de fusion de peptido similar al glucagon 1 (glp1)-factor de diferenciacion de crecimiento 15 (gdf15) y usos de estas PE20211078A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862748603P 2018-10-22 2018-10-22
PCT/IB2019/059029 WO2020084496A1 (en) 2018-10-22 2019-10-22 Glucagon like peptide 1 (glp1)-growth differentiation factor 15 (gdf15) fusion proteins and uses thereof

Publications (1)

Publication Number Publication Date
PE20211078A1 true PE20211078A1 (es) 2021-06-09

Family

ID=70330680

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021000543A PE20211078A1 (es) 2018-10-22 2019-10-22 Proteinas de fusion de peptido similar al glucagon 1 (glp1)-factor de diferenciacion de crecimiento 15 (gdf15) y usos de estas

Country Status (21)

Country Link
US (2) US11713345B2 (es)
EP (1) EP3870211A4 (es)
JP (1) JP2022513363A (es)
KR (1) KR20210081389A (es)
CN (1) CN113226351A (es)
AU (1) AU2019368816A1 (es)
BR (1) BR112021007376A2 (es)
CA (1) CA3116983A1 (es)
CL (1) CL2021000987A1 (es)
CO (1) CO2021005051A2 (es)
CR (1) CR20210193A (es)
DO (1) DOP2021000075A (es)
EA (1) EA202191105A1 (es)
EC (1) ECSP21028914A (es)
IL (1) IL282297A (es)
JO (1) JOP20210084A1 (es)
MX (1) MX2021004665A (es)
PE (1) PE20211078A1 (es)
PH (1) PH12021550885A1 (es)
SG (1) SG11202103990QA (es)
WO (1) WO2020084496A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10336812B2 (en) * 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
MX2021005908A (es) * 2018-11-20 2021-09-08 Janssen Pharmaceutica Nv Análogos de gdf15 y métodos para usarlos en la disminución del peso corporal y/o la reducción de la ingesta de alimentos.
EP4085077A4 (en) * 2019-12-31 2024-01-17 Beijing Ql Biopharmaceutical Co Ltd FUSION PROTEINS FROM GLP-1 AND GDF15 AND CONJUGATES THEREOF
US11981718B2 (en) * 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
WO2022221291A2 (en) * 2021-04-12 2022-10-20 University Of Florida Research Foundation Incorporated Compositions and methods for treating obesity
WO2022245179A1 (en) * 2021-05-21 2022-11-24 Yuhan Corporation Composition for combination therapy comprising growth differentiation factor-15 variant and glucagon-like peptide-1 receptor agonist
CN117750968A (zh) * 2021-05-21 2024-03-22 株式会社柳韩洋行 用于预防或治疗非酒精性脂肪性肝病或非酒精性脂肪性肝炎的包括生长分化因子-15变体的组合物
WO2023154953A1 (en) 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Gdf15 polypeptides for treating and preventing autoimmune diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004528014A (ja) * 2000-12-07 2004-09-16 イーライ・リリー・アンド・カンパニー Ｇｌｐ−１融合タンパク質
US20090325873A1 (en) * 2006-07-18 2009-12-31 Centocor, Inc. Human glp-1 mimetibodies, compositions, methods and uses
CN102099373A (zh) * 2008-05-22 2011-06-15 百时美施贵宝公司 基于纤连蛋白的多价支架结构域蛋白
AR075240A1 (es) * 2009-02-06 2011-03-16 Syngenta Participations Ag Modificacion de enzima multidominio para la expresion en plantas
AU2011353197B2 (en) * 2010-12-27 2017-04-20 Apo-T B.V. A cross linking polypeptide comprising an hexameric single chain antibody binding MHC-MAGE complex that induces apoptosis
DK3447069T3 (da) * 2012-11-21 2020-11-16 Janssen Biotech Inc Bispecifikke egfr/c-met-antistoffer
WO2014120619A2 (en) * 2013-01-30 2014-08-07 Ngm Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
EP3010546B1 (en) 2013-06-20 2017-08-09 Novo Nordisk A/S Glp-1 derivatives and uses thereof
PT3027642T (pt) * 2013-07-31 2020-10-30 Amgen Inc Construtos do fator 15 de diferenciação de crescimento (gdf-15)
GB201403794D0 (en) * 2014-03-04 2014-04-16 Univ Manchester Novel antimicrobial peptides
US10588980B2 (en) * 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
WO2015198199A1 (en) 2014-06-23 2015-12-30 Novartis Ag Hsa-gdf-15 fusion polypeptide and use thereof.
WO2017147742A1 (en) * 2016-02-29 2017-09-08 Eli Lilly And Company Gfral receptor therapies
US10336812B2 (en) 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof

Also Published As

Publication number Publication date
US20230322888A1 (en) 2023-10-12
CN113226351A (zh) 2021-08-06
DOP2021000075A (es) 2021-12-15
US20220089669A1 (en) 2022-03-24
AU2019368816A1 (en) 2021-05-13
EP3870211A4 (en) 2022-08-10
US11713345B2 (en) 2023-08-01
KR20210081389A (ko) 2021-07-01
JOP20210084A1 (ar) 2023-01-30
CL2021000987A1 (es) 2021-09-10
CA3116983A1 (en) 2020-04-30
JP2022513363A (ja) 2022-02-07
EA202191105A1 (ru) 2021-08-03
IL282297A (en) 2021-05-31
CR20210193A (es) 2021-06-15
SG11202103990QA (en) 2021-05-28
PH12021550885A1 (en) 2022-02-21
BR112021007376A2 (pt) 2021-08-10
MX2021004665A (es) 2021-08-24
WO2020084496A1 (en) 2020-04-30
CO2021005051A2 (es) 2021-04-30
EP3870211A1 (en) 2021-09-01
ECSP21028914A (es) 2021-05-31

Similar Documents

Publication Publication Date Title
PE20211078A1 (es) Proteinas de fusion de peptido similar al glucagon 1 (glp1)-factor de diferenciacion de crecimiento 15 (gdf15) y usos de estas
CO2017002166A2 (es) Proteínas de fusión de interleucina 2 / receptor de interleucina-2 alfa
IL279510A (en) Progranulin-FC polypeptide fusion proteins and their uses
PE20190352A1 (es) Proteinas de fusion gdf 15 y usos de estas
AR123115A1 (es) Composiciones y métodos para la degradación selectiva de proteínas
DOP2017000258A (es) Proteínas de fusión
UY36370A (es) Polipéptidos fgf-21 modificados y sus usos
ECSP064643A (es) Proteinas de fusion de glp-1
MX2021000047A (es) Proteina de fusion variante pd1-4-1bbl y procedimientos de uso de la misma.
BR112021017399A2 (pt) Proteína de fusão bifuncional e uso farmacêutico da mesma
EP3749683A4 (en) FGF21 VARIANT, FUSION PROTEIN AND USE THEREOF
CO2023017754A2 (es) Polipéptidos modificados
MX2021000263A (es) Proteina de fusion variante sirpalfa-4-1bbl y procedimientos de uso de la misma.
WO2016115511A3 (en) Vegf variant polypeptide compositions
PE20190110A1 (es) Proteinas f de prefusion del vrs estabilizadas
RU2017132689A (ru) СЛИТАЯ С Fc α-ЦЕПЬ ВЫСОКОАФФИННОГО РЕЦЕПТОРА IgE
CL2017000200A1 (es) Célula huésped mejorada para producir proteinas
EP4063385A4 (en) GIPR ANTIBODY AND FUSION PROTEIN BETWEEN THE SAME AND GLP-1, AND PHARMACEUTICAL COMPOSITION AND ASSOCIATED APPLICATION
WO2019014260A3 (en) BLOOD COMPONENT POTENTIATION OF ANTIBACTERIAL ACTIVITY OF THE LYTIC PROTEIN AND METHODS AND USES THEREOF
CO2023001488A2 (es) Proteínas de fusión del ligando para flt3 y métodos de uso
WO2020132039A3 (en) Peptide tags for ligand induced degradation of fusion proteins
CO2020016008A2 (es) Formulación de proteína de fusión estable
ECSP22049014A (es) Variantes de progranulina
EA202092698A1 (ru) Искусственный белок, содержащий антигенсвязывающую область антитела, слитый с биоактивными пептидами
EP3831855A4 (en) PEPTIDIC FUSION PROTEIN